Schedule 13G - Passive Investments
See all →NASDAQ
JPMorgan Chase & Co. has filed an amendment to its Schedule 13G, reporting a 4.0% beneficial ownership stake in Radiopharm Theranostics Limited as of December 31, 2025.
NASDAQ
SCHEDULE 13G: Regal Partners Discloses 9.05% Stake in Radiopharm
Regal Partners entities have reported a significant 9.05% beneficial ownership stake in Radiopharm Theranostics Limited, comprising over 320 million shares.
NASDAQ
Regal Funds Management Pty Limited and Regal Partners Limited have disclosed a beneficial ownership of 7.30% in Radiopharm Theranostics Limited, totaling 172,634,988 shares.
NASDAQ
JPMorgan Chase & Co. has filed an amended Schedule 13G, revealing a beneficial ownership of 9.0% in Radiopharm Theranostics Limited's American Depositary Shares.
NASDAQ
Regal Funds Management Pty Limited and Regal Partners Limited have disclosed a beneficial ownership of 9.03% in Radiopharm Theranostics Limited, totaling over 210 million shares.
NASDAQ
JPMorgan Chase & Co. has reported a 10.2% beneficial ownership stake in Radiopharm Theranostics Limited, holding 230,880,943 ordinary shares as American Depositary Shares.